[go: up one dir, main page]

MX2020012805A - Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos. - Google Patents

Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.

Info

Publication number
MX2020012805A
MX2020012805A MX2020012805A MX2020012805A MX2020012805A MX 2020012805 A MX2020012805 A MX 2020012805A MX 2020012805 A MX2020012805 A MX 2020012805A MX 2020012805 A MX2020012805 A MX 2020012805A MX 2020012805 A MX2020012805 A MX 2020012805A
Authority
MX
Mexico
Prior art keywords
same
compounds
methods
compositions
pain treatment
Prior art date
Application number
MX2020012805A
Other languages
English (en)
Inventor
Pasquale N Confalone
Scott L Dax
Original Assignee
Cersci Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cersci Therapeutics Inc filed Critical Cersci Therapeutics Inc
Publication of MX2020012805A publication Critical patent/MX2020012805A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos de fórmula (I), a composiciones que contienen los mismos, y a métodos para tratar y/o disminuir el dolor en un sujeto que lo necesita. Los compuestos de fórmula (I) son eficaces para tratar la taquifilaxia inducida por opiáceos y la hiperalgesia inducida por opiáceos.
MX2020012805A 2018-05-29 2019-05-20 Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos. MX2020012805A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862677496P 2018-05-29 2018-05-29
PCT/US2019/033140 WO2019231739A1 (en) 2018-05-29 2019-05-20 Compounds for pain treatment, compositions comprising same, and methods of using same

Publications (1)

Publication Number Publication Date
MX2020012805A true MX2020012805A (es) 2021-02-15

Family

ID=66770595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012805A MX2020012805A (es) 2018-05-29 2019-05-20 Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.

Country Status (14)

Country Link
US (3) US11091473B2 (es)
EP (1) EP3802524A1 (es)
JP (1) JP2021525269A (es)
KR (1) KR20210015892A (es)
CN (1) CN112204025B (es)
AU (1) AU2019279761A1 (es)
BR (1) BR112020024261B8 (es)
CA (1) CA3101738A1 (es)
EA (1) EA202092691A1 (es)
IL (1) IL278904A (es)
MX (1) MX2020012805A (es)
SG (1) SG11202011534YA (es)
WO (1) WO2019231739A1 (es)
ZA (1) ZA202007320B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022265960A1 (en) * 2021-06-13 2022-12-22 Daya Drug Discoveries, Inc. Prevention and treatment of neuronal damage with pyridoindolobenz[b, d] azepine compositions
WO2022266211A1 (en) * 2021-06-17 2022-12-22 Acadia Pharmaceuticals Inc. Methods of treating, ameliorating, and/or preventing osteoarthritic pain

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
FR2581063B1 (fr) 1985-04-30 1987-07-17 Chauvin Blache Lab Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5840739A (en) 1992-11-16 1998-11-24 University Of Florida Research Foundation, Inc. Thiazoline acid derivatives
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
IL149421A0 (en) 1999-11-02 2002-11-10 Depomed Inc Pharmaceutical compositions containing fed mode inducing agents
EP1251832B1 (en) 2000-02-04 2006-09-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
EP1401423A4 (en) 2001-05-29 2006-08-16 Depomed Dev Ltd METHOD FOR THE TREATMENT OF GASTROÖSOPHAGEAL REFLUX DISEASE AND NURSING ACID BREAKDOWN
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
WO2003035039A1 (en) 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20040132789A1 (en) * 2002-08-22 2004-07-08 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
NL2003786C2 (en) 2009-11-11 2010-07-30 Medner B V COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS.
EP2544542A4 (en) 2010-03-10 2013-07-24 Galleon Pharmaceuticals Inc PAIN COMPOUNDS, COMPOSITIONS AND THEIR USE
EP3070084A1 (en) * 2015-03-18 2016-09-21 Rottapharm Biotech S.r.l. New fyn kinase inhibitors
US10400264B2 (en) 2016-12-01 2019-09-03 Promega Corporation 5,5-disubstituted luciferins and their use in luciferase-based assays

Also Published As

Publication number Publication date
IL278904A (en) 2021-01-31
CN112204025B (zh) 2022-05-31
AU2019279761A1 (en) 2020-12-10
EP3802524A1 (en) 2021-04-14
KR20210015892A (ko) 2021-02-10
CA3101738A1 (en) 2019-12-05
BR112020024261B8 (pt) 2022-05-17
JP2021525269A (ja) 2021-09-24
US10844054B2 (en) 2020-11-24
WO2019231739A1 (en) 2019-12-05
US20220153731A1 (en) 2022-05-19
BR112020024261A2 (pt) 2021-02-23
US20200131170A1 (en) 2020-04-30
ZA202007320B (en) 2022-04-28
CN112204025A (zh) 2021-01-08
EA202092691A1 (ru) 2021-04-21
BR112020024261B1 (pt) 2022-05-03
US11091473B2 (en) 2021-08-17
SG11202011534YA (en) 2020-12-30
US20190367499A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
PH12022551513A1 (en) Sos1 inhibitors
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
NZ784224A (en) Parp1 inhibitors
SA520411108B1 (ar) مركبات حلقية كبيرة واستخداماتها
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
PH12022550399A1 (en) MTA-Cooperative PRMT5 Inhibitors
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
ZA201800572B (en) Therapeutic compositions, combinations, and methods of use
ZA202007007B (en) Mcl-1 inhibitors
SA520411982B1 (ar) Kirsten 2 مثبطات نظير الجين الورمي الفيروسي لساركوما جرذ (KRas) واستخدامها لعلاج السرطان
ZA201904234B (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
MY203971A (en) Anti-lag-3 antibodies and compositions
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
PH12017502123A1 (en) Substituted benzamides and methods of use thereof
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
MY195081A (en) Pladienolide Pyridine Compounds and Methods of use
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12018502314A1 (en) Enhancer of zeste homolog 2 inhibitors
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
MX2020012805A (es) Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.